Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Amortization - Deferred ChargesEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Oculis Holding AG (OCS) Receivables - Other (2021 - 2025)

Quarterly Receivables - Other rose 305.86% to $13.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.3 million through Dec 2025, up 305.86% year-over-year, with the annual reading at $13.3 million for FY2025, 305.86% up from the prior year.

Oculis Holding AG's Receivables - Other history spans 5 years, with the latest figure at $13.3 million for Q4 2025.

  • Receivables - Other came in at $13.3 million for Q4 2025, up from $3.3 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $13.3 million in Q4 2025 to a low of $1038.0 in Q4 2022.
  • The 5-year median for Receivables - Other is $2.4 million (2023), against an average of $3.8 million.
  • Year-over-year, Receivables - Other decreased 4.29% in 2022 and then surged 232859.95% in 2023.
  • Oculis Holding AG's Receivables - Other stood at $1084.5 in 2021, then dropped by 4.29% to $1038.0 in 2022, then soared by 232859.95% to $2.4 million in 2023, then skyrocketed by 35.86% to $3.3 million in 2024, then skyrocketed by 305.86% to $13.3 million in 2025.
  • Per Business Quant, the three most recent readings for OCS's Receivables - Other are $13.3 million (Q4 2025), $3.3 million (Q4 2024), and $2.4 million (Q4 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 605.66 Bn 605.66 Bn -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn
8 Evaxion A 65.12 Bn 65.10 Bn -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn
10 Oculis Holding AG 24.51 Bn 24.21 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 13.33 Mn
Dec 31, 2025 13.33 Mn
Dec 31, 2024 3.29 Mn
Dec 31, 2024 3.29 Mn
Dec 31, 2023 2.42 Mn
Dec 31, 2023 2.42 Mn
Dec 31, 2022 1,038.02
Dec 31, 2022 1,038.02
Dec 31, 2021 1,084.50
Dec 31, 2021 1,084.50